FDA kicks off review of second kidney cancer combo based on BMS’ OpdivoBristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy Share XFDA kicks off review of second kidney cancer combo based on BMS’ Opdivohttps://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/
FDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomaBristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication Share XFDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomahttps://pharmaphorum.com/news/fda-approves-bms-opdivo-and-yervoy-combination-in-first-line-mesothelioma/
BMS’ Opdivo aces trial in asbestos-linked lung cancerBristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, Share XBMS’ Opdivo aces trial in asbestos-linked lung cancerhttps://pharmaphorum.com/news/bms-opdivo-aces-trial-in-asbestos-linked-lung-cancer/
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surgeRoche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – Share XRoche’s Tecentriq claims melanoma OK, but don’t expect a sales surgehttps://pharmaphorum.com/news/roches-tecentriq-claims-melanoma-ok-but-dont-expect-a-sales-surge/
BMS gets an important win for Opdivo combination in kidney cancerBristol-Myers Squibb has staked another claim to the first-line kidney cancer market, with impressive new data for the Share XBMS gets an important win for Opdivo combination in kidney cancerhttps://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/
BMS eyes August FDA verdict for Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb is trying again to get approval for its checkpoint inhibitor combination of Opdivo and Yervoy in Share XBMS eyes August FDA verdict for Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-eyes-august-fda-verdict-for-opdivo-yervoy-in-first-line-lung-cancer/
BMS builds case for long-term use of Opdivo in kidney cancerBristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, Share XBMS builds case for long-term use of Opdivo in kidney cancerhttps://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/
BMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomaBristol-Myers Squibb’s checkpoint inhibitor combination of Opdivo and low-dose Yervoy is key to its future plans in immuno-oncology, Share XBMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomahttps://pharmaphorum.com/news/bms-opdivo-yervoy-combo-hits-a-snag-in-adjuvant-melanoma/
FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
